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Abstract
PARN, poly(A)-specific ribonuclease, regulates the turnover of
mRNAs and the maturation and stabilization of the hTR RNA
component of telomerase. Biallelic PARN mutations were associ-
ated with Høyeraal–Hreidarsson (HH) syndrome, a rare telomere
biology disorder that, because of its severity, is likely not exclu-
sively due to hTR down-regulation. Whether PARN deficiency was
affecting the expression of telomere-related genes was still
unclear. Using cells from two unrelated HH individuals carrying
novel PARN mutations and a human PARN knock-out (KO) cell line
with inducible PARN complementation, we found that PARN defi-
ciency affects both telomere length and stability and down-regu-
lates the expression of TRF1, TRF2, TPP1, RAP1, and POT1 shelterin
transcripts. Down-regulation of dyskerin-encoding DKC1 mRNA
was also observed and found to result from p53 activation in
PARN-deficient cells. We further showed that PARN deficiency
compromises ribosomal RNA biogenesis in patients’ fibroblasts and
cells from heterozygous Parn KO mice. Homozygous Parn KO
however resulted in early embryonic lethality that was not over-
come by p53 KO. Our results refine our knowledge on the pleio-
tropic cellular consequences of PARN deficiency.
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Introduction
Telomeres represent ribonucleoprotein complexes at the end of
linear chromosomes and are composed of TTAGGG repeats in
mammals. Because conventional DNA polymerases are unable to
fully replicate chromosome ends, telomeres progressively shorten
over successive cell divisions resulting in the production of short
telomeres that induce an irreversible cell cycle arrest, known as
replicative senescence (Blackburn et al, 2006). Telomere shortening
can be overcome by hTERT, the reverse transcriptase component
from the telomerase complex that also comprises dyskerin, the
accessory factors NHP2, GAR1, NOP10, and hTR/TERC used as RNA
template to produce telomeric sequences. Human telomerase is only
active in germ cells, most cancer cells, and some stem or activated
cells. Telomeric sequences warrant the binding of TRF1 and TRF2
that interact with POT1, TPP1, RAP1, and TIN2 to form the shelterin
complex that protects telomeres from degradation and fusion and
regulates telomerase recruitment and activity (de Lange, 2018).
In humans, innate defects resulting in excessive shortening or
impaired protection of telomeres cause a large spectrum of diseases
including pulmonary fibrosis, aplastic anemia, dyskeratosis congen-
ita (DC), and Høyeraal–Hreidarsson (HH) or Revesz syndromes
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(Savage, 2014; Glousker et al, 2015). HH syndrome and Revesz
syndrome are rare disorders that represent the most severe clinical
variants of DC (Alter et al, 2012; Glousker et al, 2015). HH
syndrome is characterized by early-onset bone marrow failure,
intrauterine growth retardation, microcephaly and/or cerebellar
hypoplasia, and other developmental defects (Glousker et al, 2015).
Most HH patients die in their first decade because of severe infec-
tions as a consequence of profound immunodeficiency. To date, six
genetic causes of HH have been reported, including germline muta-
tions in the genes coding for the telomerase factors dyskerin (DKC1)
and hTERT, for the shelterin components TIN2 and TPP1, and for
the DNA helicase RTEL1 (Glousker et al, 2015). Recently, biallelic
mutations in the PARN (poly(A)-specific ribonuclease)-encoding
gene were reported by four independent laboratories in a total of
nine patients as the sixth identified molecular cause of HH (Dhanraj
et al, 2015; Moon et al, 2015; Tummala et al, 2015; Burris et al,
2016).
PARN is a ribonuclease from the DEDDh subfamily of nucleases
that deadenylates poly(A) tails of RNA and therefore participates in
the controlling of mRNA stability and gene expression (Balatsos
et al, 2012). Moreover, two independent laboratories recently identi-
fied PARN as a factor involved in rRNA biogenesis in cultured
human cell lines after PARN depletion by siRNA (Ishikawa et al,
2017; Montellese et al, 2017). Additionally, PARN deadenylates
other non-coding RNAs including miRNAs, piRNAs, scaRNAs,
snoRNAs, and the human telomerase RNA component hTR/TERC
(Berndt et al, 2012; Katoh et al, 2015; Moon et al, 2015; Nguyen
et al, 2015; Tseng et al, 2015; Zhang et al, 2015; Shukla et al, 2016,
2019; Ishikawa et al, 2017; Montellese et al, 2017). PARN depletion
was initially reported to reduce hTR stability by impacting its 30-end
maturation regulation (Moon et al, 2015; Nguyen et al, 2015; Tseng
et al, 2015). Further work demonstrated that PARN, by counteract-
ing PAPD5-mediated oligoadenylation, prevents 30-to-50 degradation
of hTR by the exosome (Shukla et al, 2016). Moreover, upon PARN
depletion, the residual hTR was mislocalized into cytoplasmic foci.
As exosome inactivation rescued hTR localization into Cajal bodies
of PARN-depleted cells, it was suggested that PARN is not directly
involved in hTR localization into Cajal bodies but that the mislocal-
ization results from an increased instability of hTR RNA in these
cells (Shukla et al, 2016).
Further linking PARN mutations to telomere defects was the
interesting observation that the mRNA levels of TRF1, DKC1, and
RTEL1 were significantly down-regulated in blood cells from four
PARN-deficient patients compared to controls (Tummala et al,
2015). In the same study, siRNA-mediated PARN depletion in
human cell lines down-regulated the stability of DKC1, RTEL1, and
TRF1 mRNAs. However, the impact of PARN depletion on the
steady-state levels of these mRNAs was not investigated (Tummala
et al, 2015). As unexpected results were obtained upon PARN
knock-down (KD) in mouse myoblasts, where a decrease in tran-
script abundance could be associated with an increased stability of
the affected mRNA (Lee et al, 2012), the question remains open as
to whether PARN defects down-regulate the expression of human
telomere-related genes. In favor of this hypothesis, PARN KD in
mouse myoblasts was associated with a reduced abundance of
Terf1, Terf2, and Rtel1 gene transcripts that was, however, not
associated with a decrease in their respective mRNA half-life (Lee
et al, 2012). Intriguingly, in the same study, authors detected an
up-regulation of Terc RNA upon PARN KD (Lee et al, 2012),
suggesting some differences in PARN targets between human and
mouse.
Another important target of human PARN is p53 mRNA. In
human cancer cells, PARN KD was associated with the stabilization
of p53 mRNA (Devany et al, 2013). This, again, was not observed
in PARN-depleted mouse myoblasts (Lee et al, 2012). Recently,
Shukla et al (2019) reported that the up-regulation of p53 protein
levels resulted from the down-regulation of some specific p53
mRNA-binding miRNAs upon PARN depletion in human cancer
cells. Increased p53 levels could participate in the premature aging
phenotype of PARN-deficient cells either directly or indirectly,
through an impact on the expression of telomere-related genes.
Indeed, mice expressing the p53D31 hyperactive form of p53 were
found to be affected in their telomere metabolism through the
down-regulation of Terf1, Tinf2, Dkc1, and Rtel1 gene expression
(Simeonova et al, 2013), raising the interesting hypothesis that the
down-regulation of telomere-related genes in human PARN mutant
cells may result from p53 up-regulation (Mason & Bessler, 2015).
This hypothesis has however not been tested so far.
We here identified two unrelated HH individuals carrying novel
biallelic PARN mutations. By using PARN-mutated cells from
patients as well as a PARN knock-out human cell line generated by
CRISPR/Cas9 and carrying an inducible complementing PARN allele,
we examined the functional consequences of PARN deficiency on
telomere length and stability, expression of telomere-related genes,
and rRNA processing. We also evaluated the requirement for p53 in
the deregulation of telomere-related gene expression in cells lacking
PARN. Furthermore, a Parn KO mouse model generated by CRISPR/
Cas9 technology indicated that Parn is an essential factor in mice.
Results
Clinical features of two unrelated individuals
Individual 1 (P1) was born to a consanguineous family. She had an
older sister who died from unknown cause at 2 years of age
(Fig 1A). P1 was admitted to hospital at the age of 9 with pancy-
topenia, cerebellar ataxic gait, microcephaly, cerebellar hypoplasia,
coarse hair, and dystrophic nails (Table 1 and Appendix Fig S1).
Circulating B and NK lymphocytes were virtually absent, and bone
marrow aspirate revealed hypocellular sample with very few
hematopoietic stem cells and dysplastic megakaryocytes (Table 2).
At 11 years old, P1 had no history of severe infection and did not
require any blood or platelet transfusions.
Individual 2 (P2) was born to an unrelated non-consanguineous
family (Fig 1A). She suffered from intrauterine growth retardation
(IUGR) and, at birth, presented with hypotrophy (height and weight
below 2 standard deviation (SD)) and major microcephaly (below
6 SD) (Table 1). Cerebral MRI, performed because of cerebellar
ataxia and developmental delay, revealed cerebellar vermian and
hemispheric atrophy and atrophy of the pons. Since the first months
of life, she presented with feeding troubles (without other gastroin-
testinal symptoms or oral leukoplakia), and recurrent mild upper
and lower respiratory tract infections. Thrombopenia was diagnosed
at 6 months old, with bone marrow biopsy showing severe hypo-
plasia and dysplasia of the megakaryocytic lineage. At the age of
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10 months, she showed moderate lymphopenia, predominantly on
naı¨ve CD4 T cells and B cells (Table 2). Serum immunoglobulin
levels were normal at the age of 6 and 10 months. P2 rapidly devel-
oped progressive pancytopenia, requiring blood and platelet transfu-
sions since the age of 22 months. She died from severe bacterial
infection at 3 years old.
Overall, P1 and P2 exhibited clinical features akin to Høyeraal–
Hreidarsson syndrome (Glousker et al, 2015).
Identification of PARN mutations in individuals P1 and P2
In P1, the combined analyses of whole genome homozygosity
mapping (WGHM) and whole exome sequencing (WES) focused on
homozygous genetic variants absent from dbSNPs, EVS, 1,000 genome
and from our in-house databases (8,319 individuals) and located in
chromosomal regions co-segregating with the disease identified
homozygous mutations in the Titin-encoding gene (NM_001267550.1:
c.9413C>A; Chr2(GRCh37):g.179632544G>T; p.Ala3138Glu) and in
the PARN-encoding gene (NM_002582.2:c.204G>T; Chr16(GRCh37):
g.14721167C>A; p.Gln68His). We considered PARN gene as the stron-
gest candidate because biallelic PARN mutations had been recently
reported in HH (Dhanraj et al, 2015; Moon et al, 2015; Tummala et al,
2015; Burris et al, 2016). Sanger sequencing confirmed the homozy-
gous c.204G>T PARN mutation in P1, with both parents being
heterozygous for the mutation (Fig 1B). This variant was not listed in
gnomAD database (http://gnomad.broadinstitute.org/), further
supporting its deleterious effect. Interestingly, even though overall
sequence identities are generally low, p.Gln68 (Q68) is highly
conserved in the DEDDh subfamily of nucleases (Fig 1C) and
p.Gln68His mutation is predicted to disturb catalytic activity
(Appendix Fig S2).
In P2, WES analysis revealed a heterozygous PARN mutation
leading to a premature stop codon (NM_002582.2:c.760C>T, Chr16
(GRCh37):g.14698026G>A, p.Gln254*). This variant, absent from
gnomAD database, was inherited from her father (Fig 1D). No
PARN mutation was detected on the second allele, but we detected
several distinct RT–PCR products for PARN in both P2 and her
mother, along with a reduced abundance of P20s RT–PCR products
(Fig 1E). The heterogeneity in RT–PCR products was due to
complex splice aberrations including the skipping of one or more
exons (Appendix Fig S3A). A capture library was generated by
using a BAC covering the whole PARN gene sequence, followed
by high-throughput sequencing. Coverage analysis revealed a
twofold reduction in the abundance of the genomic region span-
ning 8,293 base pairs (Chr16:14,703,940–14,712,231) comprising
the PARN exons 6 and 7 in the mother and the patient’s cells
(Appendix Fig S3B). The heterozygous deletion was then con-
firmed by PCR (Fig 1F) and Sanger sequencing (Appendix Fig
S3C).
At the protein level, PARN was undetectable from lysates of P2’s
SV40T-transformed fibroblasts and was also strongly reduced in cell
extracts from P1 (Fig 1G). As expected, PARN down-regulation was
associated with a strong impairment of in vitro deadenylation activ-
ity on a polyadenylated RNA substrate (Fig 1H). Additionally,
mixing P1 and P2 cell extracts did not rescue the deadenylation
activity (Fig 1H), further supporting the notion that the molecular
defect was identical in P1 and P2.
Intriguingly, individual P1, although presenting with severe clini-
cal features, did not exhibit severe infection, profound anemia, or
thrombocytopenia requiring blood transfusion, as observed in most
HH cases. Sequencing analysis in a recent P1’s blood sample did not
◀ Figure 1. Identification of PARN mutations in two unrelated HH patients.A Pedigree of Patients 1 and 2 and their families.
B Direct sequencing of PARN in a control, P1, and her parents.
C Alignment of the two first conserved blocks of sequences from the DEDDh subfamily of nucleases (UniProt accession numbers). Conserved residues are colored, and
the conserved glutamine is highlighted with a red arrowhead. Secondary structures are reported on top, as observed in the experimental 3D structure of human
PARN (pdb 2A1R) (Wu et al, 2005).
D Direct sequencing of PARN in a control, P2, and her parents.
E Aberrant splicing products detected in P2 and her mother but not in P2’s father nor in a healthy control. GAPDH RT–PCR was performed as control.
F Detection of the exon 6/7 deletion by PCR with specific primers (1F/2R).
G PARN detection in cell lysates from P1 and P2 and a healthy control. Actin was used as loading control.
H In vitro deadenylation activity using protein extracts from control and P1 and P2 SV40T-transformed fibroblasts. Mixing protein extracts from control together with
P1 or P2 eliminated the deadenylation defect, whereas pairwise mixing of P1 and P2 failed to complement the deadenylation defect.
Table 1. Clinical features of patients.
Sex
Patient 1 Patient 2
Female Female
Consanguinity Yes No
Developmental features
IGR NA Yes
Prematurity NA No (37WG)
Hypotrophy Yes (< 2 SD)
Dysmorphy Yes (coarse hair,
dystrophic nails)
Yes (short neck, protruding
ears, widely spaced and
inverted nipples)
Aplastic anemia Yes Yes, progressive
Immunodeficiency Yes Yes
Neurological features
Microcephaly Yes Yes (< 6 SD)
Cerebellar atrophy Yes Yes
Other No Atrophy of the pons
Gastrointestinal features No Feeding troubles since the
neonatal period
Skin features No No
Outcome Alive at 11 years
of age without
severe infection
Death at 3 years of age
after severe infection
NA, not available.
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reveal any somatic genetic modification in PARN (data not shown),
ruling out the possibility of a spontaneous genetic reversion or
correction as reported in other hematologic genetic disease (Le Guen
et al, 2015; Tesi et al, 2017). Somatic TERT promoter-activating
mutations in blood cells leading to increased telomerase expression
can also counteract the deleterious effect of inherited heterozygous
loss-of-function mutations in hTERT, hTERC, or PARN (Maryoung
et al, 2017; Gutierrez-Rodrigues et al, 2018). However, sequencing
analysis of TERT promoter in P1’s blood cells did not either reveal
any variant that could explain the relative mild hematologic pheno-
type (data not shown).
Telomere length defect and telomere instability in
PARN-mutated cells from P1 and P2
We first assessed whether PARN deficiency in patients was accom-
panied by a telomere length defect as previously reported (Dhanraj
et al, 2015; Moon et al, 2015; Tummala et al, 2015; Burris et al,
2016). Telomere restriction fragment (TRF) measurement revealed
abnormally short telomeres in peripheral blood mononuclear cells
from P1 and P2 as compared to their parents (Fig 2A). Quantitative
telomeric FISH (qTelo-FISH) on patients’ SV40T fibroblasts, using
Muntjac cells to normalize the fluorescence intensity of telomeric
FISH signal (Zou et al, 2002), confirmed the short telomere pheno-
type in P1 and P2 (Fig 2B–D). The short telomere phenotype
observed in patients’ cells was accompanied by telomere dysfunc-
tion, detected by the presence of DNA repair factor 53BP1 at telom-
eres, known as TIF (telomere dysfunction-induced foci) (d’Adda di
Fagagna et al, 2003; Takai et al, 2003; Fig 2E and F). Accordingly,
primary fibroblasts from P1 showed a significant increase in cellular
senescence, as assessed by the senescence-associated (SA)–b-galac-
tosidase activity assay, when compared to two healthy controls at
similar passage (Fig 2G). Due to a severe growth defect of P2’s
primary fibroblasts, TIF and senescence analyses could not be
performed in these cells.
Next, we assessed whether the telomere length defect of P1 and
P2 was associated with any telomere instability. Telomeric FISH
performed on metaphase spreads of SV40T-transformed fibroblasts
at early passages revealed a statistically significant increase in termi-
nal deletions (Fig 2H and I) and telomere sister loss (Fig 2H–J) in
both patients’ cells, while multiple telomeric signals and telomere
fusions were not overrepresented (not shown). These results
suggested that, in addition to accelerated telomere shortening,
PARN-mutated cells from patients exhibited increased telomere
instability.
PARN regulates the expression levels of telomere-related gene
transcripts, but not TERRA
In light of the possible impact of PARN on mRNA levels of shelterin
genes (Tummala et al, 2015), the increased telomere instability
observed in P1 and P2’s cells may be related to a down-regulation
of shelterin gene expression. Previous work from Tummala et al
(2015) reported that transient depletion of human PARN was associ-
ated with a decreased stability of DKC1, RTEL1, and TRF1 tran-
scripts, but a comparison of the steady-state mRNA levels was not
provided. To assess the impact of stable PARN depletion on the
expression of telomere-related genes and to perform functional
Table 2. Immunological features of patients.
Age
Patient 1 Patient 2
9 years 11 years 6 months 10 months 23 months
White cell count—×109/l 2.7 (5.5–15.5) 3.3 (5.5–15.5) 8.8 (6–17.5) 6.7 (6–17.5) 3.1 (6–17.5)
Polymorphonuclear neutrophils—×109/l 1.1 (1.8–8.0) 1.4 (1.8–8.0) 3.0 (1.5–8.5) 3.2 (1.5–8.5) 0.8 (1.5–8.5)
Lymphocytes—×109/l NA NA 4.4 (3.0–9.5) 2.3 (3.0–9.5) 2.2 (3.0–9.5)
Hemoglobin—g/dl 10 (11.5–13.5) 7.1 (11.5–13.5) 11.9 (10.5–12.0) 12.1 (10.5–12.0) 7.3 (10.5–12.0)
Platelets—×109/l 29 (175–420) 37 (175–420) 67 (175–500) 38 (175–500) 5 (175–500)
Reticular platelets—% NA NA NA 6.5 (1.0–7.0) NA
T cells—% (normal range)
CD3+ 88 (60–76) 92 (60–76) 73 (49–76) 84 (49–76) NA
CD4+ 47 (31–47) 31 (31–47) 40 (31–56) 41 (31–56) NA
CD31+CD45RA/CD4+ 27 (43–55) NA NA 37 (60–72) NA
CD8+ 41 (18–35) 59 (18–35) 15 (12–24) 33 (12–24) NA
B CD19+ cells – % 0.1 (13–27) 2 (13–27) 19 (14–37) 12 (14–37) NA
Natural killer CD16+CD56+ cells— % 0.1 (4–17) NA 7 (3–15) 4 (3–15) NA
Serum immunoglobulins level: g/l
IgG NA 9.76 (6.55–12.29) 3.35 (3.35–6.23) 5.30 (3.35–6.23) NA
IgA NA 1.74 (0.5–2.03) 0.41 (0.27–0.86) 0.43 (0.27–0.86) NA
IgM NA 1.21 (0.53–1.62) 1.27 (0.48–1.36) 0.52 (0.48–1.36) NA
For all values, normal range or normal thresholds are indicated in brackets. Abnormal low values are highlighted in bold.
NA, not available.
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studies on telomeres from these cells, we generated PARN knock-
out (KO) mutants in the telomerase- and p53-positive human cell
line HT1080 through CRISPR/Cas9 mutagenesis. We obtained a
PARN KO clone (HT1080PARN KO) carrying PARN frameshift
mutations on both alleles (1 bp deletion on one allele and 1bp inser-
tion on the other, Appendix Fig S4), leading to a complete loss of
PARN protein (Fig 3A). Accordingly, HT1080PARN KO cells exhibited
a defective in vitro deadenylation activity on a poly-(A) RNA
20µm
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Figure 2.
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substrate (Fig 3B) and reduced telomerase activity (Fig 3C) associ-
ated with a down-regulation of hTR transcripts (Fig 3D). Addition-
ally, as recently reported in PARN knock-down cells (Shukla et al,
2016), RNA-FISH revealed a mislocalization of hTR to the cytoplasm
of HT1080PARN KO cells (Fig 3E). Next, HT1080PARN KO cells were
transduced with either control pCW57 plasmid encoding GFP
(“empty”) or pCW57-PARN plasmid carrying an inducible WT
PARN coding sequence (“indPARN”). Doxycycline-induced expres-
sion of PARN (Fig 3F) was found to complement the defective dead-
enylation activity of HT1080PARN KO cells (Fig 3G). For sake of
simplicity, cell lines will be denominated as follows: WT/empty,
WT/PARN, KO/empty, and KO/PARN.
qRT–PCR experiments confirmed the involvement of PARN in
hTR RNA transcript abundance (P=0.001) and supported the PARN-
dependent impact on telomere-related gene transcripts since the
complementation of HT1080PARN KO cells by WT PARN rescued the
transcript levels of TRF1 (P = 0.003), TRF2 (P = 0.0002), POT1
(P = 0.001), DKC1 (P = 0.05), and TPP1 (P = 0.0004) found to be
down-regulated in KO/empty cells (Fig 3H). In our system, the
impact of PARN KO was the strongest for TRF2, with a more than
twofold reduction in transcript abundance associated with a down-
regulation at the protein level (Fig 3H and I). Although differences
did not reach statistical significance, RAP1 and RTEL1 transcripts
were also down-regulated in KO/empty cells (Fig 3H).
In agreement with previous reports showing that PARN depletion
increases p53 mRNA levels by ~1.7–1.9-fold (Zhang & Yan, 2015;
Shukla et al, 2019) p53 transcript levels were increased by about
twofold in KO/empty cells (P = 0.001) (Fig 3J). Up-regulation at the
protein level was of about twofold as well (Fig 3I). Surprisingly
however, p53 levels (mRNA or protein) were not reduced back in
PARN-complemented cells (Fig 3I and J). Similar results were
obtained for p21 mRNA levels that displayed a more than twofold
increase in KO/empty cells (P = 0.0009) but failed to return to WT
levels after PARN complementation (Fig 3J). These observations
were reminiscent to the previously proposed adaptation of PARN-
depleted cells through the up-regulation of other cellular deadeny-
lases (Zhang & Yan, 2015).
TElomeric Repeat-containing RNAs (TERRA), the telomeric non-
coding RNAs transcribed from subtelomeric promoters, also partici-
pate in telomerase regulation and telomere protection (Azzalin et al,
2007; Chu et al, 2017). Because PARN deadenylase substrates include
other non-coding RNAs like miRNAs, piRNAs, scaRNAs, snoRNAs, we
next examined whether PARN depletion may affect TERRA levels. To
avoid any bias due to distinct telomere lengths, previously found to
affect TERRA abundance (Arnoult et al, 2012), we quantified TERRA
molecules produced from various chromosome ends in HT1080PARN KO
cells complemented or not with PARN. Our qRT–PCR analyses did not
however reveal any impact of PARN on TERRA levels (Fig 3K).
◀ Figure 2. Short and dysfunctional telomeres in cells from HH patients.A Mean telomere length (kb) of whole blood cells from patients and their parents estimated with the TRF method.
B Representative picture of telomeric signals used for Q-FISH analysis on metaphase spreads from SV40T-transformed fibroblasts and Muntjac cells used to normalize
the signals.
C Individual and mean values of Q-FISH analyses for control and patients. Mean fluorescence intensity of Muntjac cells was set to 1. Error bars indicate s.d.
D Graphical representation of (C) showing the average of fluorescence ratios (relative to Muntjac). Error bars indicate s.e.m. The non-parametric Kruskal–Wallis test
was applied to compare relative fluorescence values between Ctl and P1, and Ctl and P2 3 independent experiments.
E Representative pictures of nuclei from two controls and patient’s primary fibroblasts showing 53BP1 foci (green) and telomeres (red, detected by Telo-FISH). Yellow
arrows indicate telomere dysfunction-induced foci (TIF). The scale bar corresponds to 5 lm.
F Quantification of (E) in primary fibroblasts from two healthy controls (passages > 4) and from Patient 1 (passages < 4). Control 1: n = 224; Control 2: n = 263;
Patient 1: n = 231. Averages are shown, and error bars indicate s.e.m.. Unpaired Student’s t-tests were applied when indicated.
G Representative pictures of SA–b-galactosidase staining in control (passage 15) and P1’s primary fibroblasts (passage 6). Results are expressed as the percentage of
SA–b-galactosidase-positive cells (averages, lower panel). Control: n = 436; P1: n = 436. A test to compare two population proportions was applied.
H Representative pictures of chromosomes with normal or aberrant telomeres detected by Telo-FISH. The scale bar corresponds to 1 lm. Arrowheads indicate
chromatid ends lacking telomeric signal.
I, J Quantification of terminal deletions (I) and sister telomere losses (J) from three independent experiments (counted chromatids: Ctl1: n = 2,224; Ctl2: n = 5,696;
P1: n = 4,764; P2: n = 7,908). Averages are shown, and chi-square tests were applied to compare Ctl1/2 with either P1 or P2.
▸Figure 3. PARN KO cells display reduced telomerase activity and down-regulation of shelterin and telomere-related gene expression.A Validation of PARN KO in HT1080 cells by Western blot. GAPDH is used as loading control.
B In vitro deadenylation activity assay using protein extracts from HT1080 (WT) and HT1080PARN KO (PARN KO) cells.
C TRAP assay using successive dilutions (500, 250, 125, and 62.5 ng) of cell extracts from WT or PARN KO cells. An internal control (IC) for PCR was used.
D qRT–PCR analysis of hTR expression in WT and PARN KO cells. Expression levels were normalized first to ACTB and then to WT. Three independent RNA extractions
were performed for each cell line. Error bars indicate s.e.m.
E Representative pictures of FISH against hTR in WT and PARN KO cells. Arrows indicate hTR foci. Scale bar 5 lm.
F PARN detection by Western blot in the indicated conditions. Expression was induced by incubating cells with 10 ng/ml doxycycline for 72 h. Actin is used as loading
control. PARN/actin ratios, normalized to doxycycline-treated WT/PARN cells, are shown below.
G In vitro deadenylation activity assay using protein extracts from doxycycline-treated WT/empty, WT/PARN, KO/empty, and KO/PARN cells.
H qRT–PCR analysis of the indicated gene transcripts in doxycycline-treated WT/empty, WT/PARN, KO/empty, and KO/PARN cells. Expression levels were normalized first
to ACTB and then to WT/empty. Three independent doxycycline inductions were performed for each cell line. Averages are shown, and error bars indicate s.e.m.
Unpaired Student’s t-tests were applied.
I Representative Western blot analysis of PARN, TRF2, and p53. Actin was used as loading control. Mean TRF2/actin levels from two independent experiments are
indicated below.
J Same as (H) for p53 and p21 transcripts. Averages are shown, and error bars indicate s.e.m. Unpaired Student’s t-tests were applied. Three independent doxycycline
inductions were performed for each cell line.
K qRT–PCR analysis of TERRA from the indicated chromosome ends in doxycycline-treated KO/empty and KO/PARN cells. Expression levels were normalized first to ACTB
and then to KO/empty. Three independent doxycycline inductions were performed for each cell line. Error bars indicate s.e.m.
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Telomere instability in HT1080PARN KO cells is independent of
telomere length
As the defective expression of telomere-related genes may induce
telomere instability, we next tested whether the telomere instability
observed in PARN-deficient cells from patients (Fig 2I and J) was
also detected in HT1080PARN KO cells. Accordingly, telomeric FISH
revealed a significant increase in terminal deletions, telomere sister
losses, telomere–telomere fusions, and multiple telomeric signals in
KO/empty compared to WT/empty cells (Fig 4A). Strikingly, the
telomeric aberrations were abolished after PARN induction via 72h
of Dox treatment in HT1080PARN KO cells (Fig 4A). Since the induc-
tion of WT PARN during 72h was not sufficient to globally modify
telomere length (Fig 4B), we concluded that the telomere instability
of HT1080PARN KO cells was independent of telomere length. There-
fore, this result suggests that PARN participates in telomere stability,
possibly through the regulation of telomere-related gene expression.
Down-regulation of DKC1 transcripts in HT1080PARN KO cells is
dependent on p53
Our observations that, despite the lack of p53 mRNA rescue in
PARN-complemented HT1080PARN KO cells, the expression levels of
hTR, TRF1, TRF2, POT1, TPP1, RAP1, and RTEL1 were restored
(Fig 3H) suggested that p53 was not involved in the down-regulation
of these gene transcripts. On the contrary, DKC1 transcript levels
were not restored upon PARN induction in complemented cells
(Fig 3H). To further investigate the involvement of p53 in DKC1
down-regulation upon PARN depletion, we transiently knocked
down p53 using siRNAs in WT/empty and KO/empty cells (Fig 5A).
Although p53 knock-down did not suppress the down-regulation of
hTR, TRF1, TRF2, POT1, TPP1, or RTEL1 transcripts levels, DKC1
mRNA levels were similar in WT/empty and KO/empty cells treated
with sip53, suggesting that DKC1 down-regulation is a consequence
of p53 induction (Fig 5B). To verify whether this p53-dependent
impact on DKC1 transcripts may also apply to cells from HH patients,
we compared DKC1 levels in primary and SV40T-transformed fibrob-
lasts from P1 (SV40T is known to deregulate p53 activity; Ahuja
et al, 2005). Accordingly, we detected a strong up-regulation of
DKC1 transcript levels in SV40T fibroblasts of P1 patient (Fig 5C).
Conversely, and further supporting their independence from p53,
other transcripts, including hTR or TRF1, were not up-regulated in
SV40T-transformed fibroblasts from P1 (Fig 5C).
Defective ribosomal RNA biogenesis in PARN-deficient cells
Recently, PARN was identified as the exonuclease that trims the 30
end of 18S-E pre-ribosomal RNA (pre-rRNA; Ishikawa et al, 2017;
A B
Figure 4. PARN KO cells display telomere instability independently of telomere length.
A Analysis of telomeric aberrations by Telo-FISH in doxycycline-treated WT/empty, WT/PARN, KO/empty, and KO/PARN cells. Two independent experiments were
performed. Counted chromatids: WT/empty: n = 1,824; WT/PARN: n = 1,744; KO/empty: n = 1,452; KO/PARN: n = 1,920. Averages are shown, and chi-square tests
were applied to compare KO/empty with either WT/empty or KO/PARN.
B TRF analysis of telomere length (kb) in KO/empty and KO/PARN cells treated with 10 ng/ml Dox for 72 h. A control Western blot with PARN and actin is shown below
for the corresponding samples.
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Montellese et al, 2017), the last precursor to the 18S rRNA. The
full-length 18S-E pre-rRNA (18S-EFL) generated by endonucleolytic
cleavage by hUTP24 at site E is then submitted to exonucleolytic
trimming by PARN before export to the cytoplasm (Appendix Fig
S5; Wells et al, 2016). Interestingly, we found that rRNA biogene-
sis is impaired in patients with a marked accumulation of 18S-E
pre-rRNAs in P1 and P2’s cells relative to control cells (Fig 6A–D,
50ITS1 probe, and Appendix Fig S5) Moreover, as expected from
PARN loss of function, untrimmed 18S-EFL precursors were
detected in P1 and, to a lesser extent, in P2’s cells, while they
were hardly detected in control cells (Fig 6C and D, ITS1-59
probe). The 18S/28S ratios were unchanged in patient cells despite
this deficient processing, consistent with previous observation that
the 30 end of 18S rRNA precursors unprocessed by PARN can still
be matured, albeit less efficiently, by endonuclease NOB1. As
previously reported for PARN-depleted cell lines (Ishikawa et al,
2017; Montellese et al, 2017), the processing defect in P1 and P2’s
cells only impacted the 18S rRNA pathway, but did not affect 5.8S
nor 28S precursors (ITS2 probes). A closer examination further
revealed an accumulation of 30S+1 pre-rRNAs in P1 (50ETS probe),
while these precursors were very sparse in control and P2
(Fig 6C). This defect in very early cleavage at site A’ was not
observed upon the mere knock-out of PARN, and could correspond
to a specific impact of the homozygous Gln68His PARN mutation,
which remains to be investigated.
rRNA biogenesis was also affected in HT1080PARN KO relative to
HT1080PARN WT cells as revealed by a sharp increase in 18S-E and 18S-
EFL pre-rRNAs (Fig 6E and G). Importantly, induction of WT PARN
expression complemented the defect observed in HT1080PARN KO cells,
with a strong reduction of 18S-E and 18S-EFL precursors to the levels
observed in HT1080PARN WT cells (Fig 6F and G). The rescue of defec-
tive rRNA biogenesis in PARN-complemented HT1080PARN KO cells
that, as detailed earlier, keep high levels of p53 further suggests that
the impact of PARN depletion on rRNA biogenesis occurs indepen-
dently of p53.
Early embryonic lethality of Parn KO mice
To investigate the consequences of PARN deficiency in vivo, we
generated a Parn KO mouse model by using CRISPR/Cas9 technol-
ogy. We selected two F0-derived F1 mice, Parn#25+/ and
Parn#29+/, that carried, respectively, heterozygous 1 bp deletion
and 2 bp deletion in the Parn coding sequence, both predicted to
generate frameshift and premature stop codon (Appendix Fig S6).
Parn #25+/ and Parn#29+/ were crossed onto C57BL/6 to segre-
gate the CRISPR/Cas9-generated mutant alleles. SV40-transformed
mouse embryonic fibroblasts (MEFs) obtained from Parn#25+/
confirmed the twofold reduction in Parn protein levels (Fig 7A).
Interestingly, these MEFs also exhibited a strong accumulation of
18S-E pre-rRNAs (Fig 7B and C, 50ITS1 probe). Unlike what was
observed in human cells however, Parn haploinsufficiency also
induced a moderate accumulation of 12S pre-rRNAs, along with
slightly shorter precursors (ITS2 probes). This could be indicative
of an involvement of mouse PARN in 12S pre-rRNA early process-
ing or a quality control process, not found in human cells (Ishi-
kawa et al, 2017; Montellese et al, 2017). Altogether, our data
attest for a biological impact of Parn haploinsufficiency in MEFs
and suggest a conserved function for mouse Parn in 18S rRNA
biogenesis.
Parn#25+/ or Parn#29+/ mice were interbred to obtain
Parn/ animals. However, crosses yielded no homozygous null
pup (Fig 7D; 96 animals screened; P = 1.5E-08, chi-square test)
and we could not either detect any null embryo at E11.5 (Fig 7E;
n = 15 screened; P = 0.002535, chi-square test), arguing for an
early embryonic lethality that occurs too early in development for
cell lines to be derived. PCR amplification and direct sequencing in
Parn+/ heterozygous animals of the seven genomic loci predicted
to be putatively off-targeted did not reveal any mutation, ruling
out any off-target effect (Appendix Table S1). Since p53 deficiency
was previously reported to rescue the deleterious effects of aber-
rant short telomeres (Chin et al, 1999), we next tested whether the
A B C
Figure 5. Down-regulation of DKC1 mRNA in PARN KO cells is dependent on p53.
A HT1080 (WT) and HT1080PARN KO (KO) cells stably transfected with GFP plasmid (empty) were transfected with siRNAs against p53 for 72h before RNA extraction and
qRT–PCR. siRNAs against luciferase (siLuci) were used as control. p53 expression levels were normalized first to ACTB and then to WT/empty/siLuci cells. Experiment
was performed in triplicate. Error bars indicate s.e.m.
B Cells were treated as in (A), and transcript levels of the indicated genes were measured by qRT–PCR. cDNA expression levels were normalized first to ACTB and then to
WT/empty/siLuci cells. Experiment was performed in triplicate. Error bars indicate s.e.m.
C qRT–PCR analyses of the indicated genes were performed on RNA extracted from P1’s primary or SV40T-transformed fibroblasts. cDNA expression levels were
normalized to primary fibroblasts. Two independent RNA extractions were performed. Error bars indicate s.e.m.
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lack of p53 could abolish the embryonic lethality of Parn-deficient
embryos. However, the crossing of Parn+/ p53+/ animals with
either Parn+/ p53+/ (Fig 7F) or Parn+/ p53/ mice (Fig 7G)
did not retrieve any mouse deficient for both p53 and Parn (a total
of 105 animals were screened; P = 0.000886, chi-square test).
Thus, these results indicated that Parn deficiency in mouse leads
to embryonic lethality before stage E11.5 that is not overcome by
the absence of p53.
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Figure 6.
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Discussion
Disease resulting from biallelic PARN mutations has been reported
in only 9 patients so far (Dhanraj et al, 2015; Moon et al, 2015;
Tummala et al, 2015; Burris et al, 2016). We here describe two
unrelated patients carrying novel biallelic PARN mutations and
exhibiting a phenotype corresponding to Høyeraal–Hreidarsson
syndrome. PARN, via its control of hTR maturation and stabiliza-
tion, participates in telomerase activity and consequently in telom-
ere maintenance (Moon et al, 2015). However, the clinical severity
of PARN-deficient patients, including ours, suggests that, besides
hTR down-regulation, other important biological processes may be
impaired. In this study, we generated a HT1080PARN KO cell line
carrying an inducible complementing PARN allele to carefully exam-
ine the consequences of PARN depletion in human cells. We con-
firmed the reduced hTR expression and its mislocalization to the
cytoplasm of PARN KO cells (Shukla et al, 2016) and found a down-
regulation of TRF1, TRF2, POT1, TPP1, and DKC1 mRNA levels. We
also observed an induction of p53 mRNA and protein levels by
about twofold.
Importantly, we found that PARN-depleted cells exhibit multi-
ple telomeric defects reminiscent to those reported in shelterin-
deficient cells (Sfeir & de Lange, 2012). Most telomeric aberra-
tions were rescued after 72 h of PARN induction, together with a
complete rescue of TRF1, TRF2, POT1, and TPP1 mRNA levels.
Since the 72-h treatment with doxycycline was not sufficient to
promote telomerase-dependent re-elongation of telomeres, our
study suggests that PARN is able to promote telomere stability
independently of telomere length, likely by regulating shelterin
expression. On the other hand, complementation by PARN did
not rescue DKC1 mRNA levels in PARN KO cells. Our data indi-
cated that the down-regulation of DKC1 mRNA levels in PARN
KO cells was dependent on p53 induction in these cells (Fig 8),
in agreement with the previous observation that the hyperactive
p53D31 allele down-regulates DKC1 expression in mouse cells
(Simeonova et al, 2013). Supporting a role for up-regulated p53
in the down-regulation of DKC1 mRNA in PARN-depleted cells,
we found that p53 expression levels were not back to normal
upon complementation with PARN. In light of these results, we
conclude that the impact of PARN depletion on TRF1, TRF2,
POT1, and TPP1 mRNA levels is independent on p53 induction
(Fig 8). Similar to what was recently reported for p53 mRNA
(Shukla et al, 2019), PARN deadenylase activity may stabilize the
mRNAs of these telomere-related genes through the up-regulation
of some miRNAs. Alternatively, PARN may directly stabilize
TRF1, TRF2, POT1, and TPP1 mRNAs by deadenylating their 30
ends. Additional experiments will be needed to understand how
PARN modulates the mRNA levels of telomere-related genes.
The reason why PARN complementation failed to rescue p53
mRNA levels in our experimental cellular system is currently
unknown but fits with the previous hypothesis that depletion of
PARN may induce compensatory cellular mechanisms through the
up-regulation of other deadenylases, including the Ccr4a, b, or d
enzymes (Zhang & Yan, 2015). Along this line, we detected an up-
regulation of hCcr4d mRNA in the PARN KO cells (data not shown).
Our results also provide evidence that PARN does not directly regu-
late global TERRA biogenesis or degradation, suggesting that the
negative impact of PARN depletion on telomere stability is not due
to deregulated TERRA levels.
We further showed that both PARN-deficient patient cells and
PARN KO cells exhibited defective rRNA biogenesis that was
reverted by PARN complementation, thus establishing that defective
rRNA biogenesis in a PARN-deficient context is not due to p53
dysregulation.
Altogether, the experimental cellular system that we developed
to study the multiple consequences of PARN depletion revealed an
important role for the enzyme in telomere elongation, telomere
stability, and rRNA biogenesis, and clarified the impact of the asso-
ciated p53 up-regulation, previously proposed to be central in the
cellular phenotypes of telomere-related mutations (Mason & Bessler,
2015). Our data indicate that, in the context of PARN depletion, p53
up-regulation may only down-regulate a limited number of telom-
ere-related genes and is not the cause of telomere instability or
impaired rRNA biogenesis (Fig 8). Further supporting our results
with the experimental human cellular system was the observation
that the early embryonic lethality of the PARN KO mice we devel-
oped by CRISPR/Cas9 was not compensated by p53 depletion.
Because mTR/ and mTERT/ mice are viable (Blasco et al, 1997;
Liu et al, 2000), these data are consistent with Parn having essential
roles besides its function in telomerase activity. Accordingly, we
confirmed that mouse PARN participates in rRNA biogenesis.
Altogether, our study strongly supports the involvement of
PARN enzyme in multiple important biological pathways, in both
mouse and humans, which, together, likely contribute to the patho-
physiology of the disease (Fig 8). The lethality of Parn KO mice
suggests that the severe PARN mutations identified in patients are
either hypomorphic or lead to the acquisition of compensatory
mechanisms through, for instance, the up-regulation of other
◀ Figure 6. PARN dysfunction impacts human pre-ribosomal RNA processing.A Schematic representation of human ribosomal precursors with rRNAs sequences displayed as gray (18S, small ribosomal subunit) or white boxes (5.8S and 28S rRNAs,
large ribosomal subunit). These three rRNAs are flanked by external (50ETS, 30ETS) and internal transcribed spacers (ITS1, ITS2). The position of endonucleolytic
cleavages is represented by vertical lines along these transcribed spacers or corresponds to 50 and 30 ends of rRNA sequences.
B Graphical representation of DNA probes used for Northern blot hybridization displayed along the 47S primary rRNA transcript.
C Northern blot analysis of pre-rRNAs from control and patient B-LCLs.
D Log2 values of 18S-E/21S and 18S-EFL/21S for P1 and P2 were normalized to the values of the control and presented in a graphical format, with Log
averages  standard deviation for two independent experiments.
E Northern blot analysis of pre-rRNAs from HT1080PARN WT and HT1080PARN KO cells, transduced with an empty vector.
F Ectopic expression of PARN was induced in HT1080PARN KO cells and compared to cells transduced with an empty vector. Western blot relative to actin assessed PARN
levels.
G Quantitative analyses of 18S-E/21S and 18S-E FL/21S ratios were as described in (D) for HT1080PARN KO cells relative to HT1080PARN WT (left panel; see (E)) and for
HT1080PARN KO cells rescued by ectopic expression of PARN relative to HT1080PARN KO cells transduced with an empty expression vector (right panel; see (F)), with Log
averages  standard deviation for four independent experiments.
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Figure 7. The early embryonic lethality of Parn KO is not rescued in p53/ mice.
A Western blot analysis of Parn expression in control and Parn+/ MEFs.
B Northern blot analysis of total RNAs from WT and Parn+/ MEFs.
C Schematic representation of mouse rRNA precursors and position of DNA probes used in Northern blot.
D Frequencies of expected and observed newborns of the indicated genotype obtained from Parn+/ intercrosses. n indicates the number of animals analyzed.
Statistical significance (P = 1.5417E-08) of the differences between the observed and expected genotype distributions was assessed by chi-square test.
E Frequencies of expected and observed E11.5 embryos of the indicated genotype obtained from Parn+/ intercrosses. n indicates the number of animals analyzed.
Statistical significance (P = 0.02535) of the differences between the observed and expected genotype distributions was assessed by chi-square test.
F, G p53 knock-out does not rescue Parn/. No Parn/ p53/ mouse was born from various combinations of Parn+/ and either p53+/ or p53/ crosses (49 and 56
pups, respectively). Statistical significance (P = 0.000886) of the differences between the observed and expected genotype distributions was assessed by chi-square
test.
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deadenylases. Heterozygous PARN mutations have been associated
with idiopathic pulmonary fibrosis and rheumatoid arthritis-intersti-
tial lung disease associated with short telomeres (Stuart et al, 2015;
Juge et al, 2017). Our experiments with Parn+/ MEFs revealed
that PARN amount is limiting in cells. A careful follow-up of
parents carrying heterozygous PARN mutation is therefore needed
to anticipate potential development of pulmonary fibrosis, progres-
sive bone marrow failure, or other ailments associated with prema-
ture aging.
Materials and Methods
Study approval
Informed and written consent was obtained from donors, patients,
and families of patients. The study and protocols comply with the
1975 Declaration of Helsinki as well as with the local legislation and
ethical guidelines from the Comite´ de Protection des Personnes de
l’Ile de France II and the French advisory committee on data
processing in medical research. A consent was obtained from the
parents of P1 to publish the patient’s photographs.
Cells
Control fibroblasts were obtained from skin biopsies from pediatric
healthy donors (3 years of age). Control fibroblasts were indif-
ferently from healthy male or female donors (no difference in
phenotype was noticed with gender). Fibroblasts were transformed
by the large T antigen from SV40T as previously described (Buck
et al, 2006). The HT1080 human fibrosarcoma cell line was kindly
provided by Arturo London˜o-Vallejo (Institut Curie, Paris, France).
All cell lines were checked for mycoplasma contamination.
Whole exome sequencing
Exome capture was performed using the SureSelect Human All Exon
Kit (Agilent Technologies, Santa Clara, CA). Agilent SureSelect
Human All Exon (54 Mb, Clinical research Exome) libraries were
prepared from 3 lg of genomic DNA sheared with an Ultrasonicator
(Covaris, Woburn, MA) as recommended by the manufacturer.
Barcoded exome libraries were pooled and sequenced using a
HiSeq2500 (Illumina, San Diego, CA) generating 130 × 130 paired-
end reads. After demultiplexing, sequences were mapped on the
human genome reference (NCBI build37/hg19 version) with BWA.
Figure 8. The multiple substrates of PARN in telomere biology and rRNA biogenesis.
PARN regulates the expression of telomere-related gene transcripts, including shelterin transcripts and the hTR RNA component of telomerase. How PARN stabilizes hTR has
been well described and involves its 30-end deadenylation. However, at present, the mechanisms underlying PARN-dependent regulation of telomere-related gene transcripts
are still unknown and may involve direct or indirect regulations through 30-end deadenylation of either the shelterin mRNAs or some miRNAs that bind to these mRNAs.
Our data also show that PARN regulates the level of DKC1 mRNA through the control of p53 levels. Taken together, PARN impacts on both telomere stability and telomere
length. An additional role of PARN is to regulate rRNA maturation in both human and mouse cells. Our data suggest that PARN-dependent regulation of rRNA maturation
occurs independently of p53. The involvement of PARN in various aspects of cell biology likely explains the severity of the phenotype in Høyeraal–Hreidarsson syndrome
patients carrying biallelic PARN mutations.
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The mean depth of coverage obtained from the exome library was
138X with > 99% of the targeted exonic bases covered by at least 15
independent reads and > 97% by at least 30 independent sequencing
reads (> 99% at 15× and > 97% at 30×). Variant calling was carried
out with the Genome Analysis Toolkit (GATK), SAMtools, and Picard
Tools. Single nucleotide variants were called with GATK Unified
Genotyper, whereas indel calls were made with the GATK IndelGeno-
typer_v2. All variants with a read coverage ≤ 2× and a Phred-scaled
quality of ≤ 20 were filtered out. All the variants were annotated and
filtered using Polyweb, an in-house developed annotation software.
Constructs and cDNA analysis
Total RNA from patient and control fibroblasts or B-LCL was
extracted using TRIzol reagent (Invitrogen, Grand Island, NY)
according to the manufacturer’s instructions. Reverse transcription
was performed using a SuperScript First-Strand Synthesis Kit (Invit-
rogen). Nucleotide numbering reflects cDNA numbering with +1
corresponding to the A of the ATG translation initiation codon in
the reference sequence. The initiation codon is codon 1. PARN ORF
was PCR-amplified from cDNA and cloned into an inducible
pCW57-lentiviral vector by replacing the GFP cassette for comple-
mentation experiments (Addgene Plasmid #71783).
Targeted resequencing by NGS (capture by hybridization
approach) to detect copy number variations
Illumina compatible barcoded genomic DNA libraries were
constructed according to the manufacturer’s instructions (Ovation
Ultralow, NuGen Technologies). Briefly, 1–3 lg of each patient’s
genomic DNA was mechanically fragmented to a median size of
200 bp using a Covaris sonicator. 100 ng of fragmented dsDNA was
end-repaired, and adaptors containing a specific 8 bases barcode were
ligated to the repaired ends. DNA fragments were then PCR-amplified
to get the final pre-capture barcoded libraries that were pooled at
equimolar concentrations (a pool of 15 libraries was prepared). The
capture process was performed using SureSelect reagents (Agilent),
750 ng of the pool of pre-capture libraries, and home-made biotiny-
lated probes. The biotinylated ssDNA probes were designed and
prepared to cover a 194-kb chromosomal region including the
complete PARN gene on chromosome 16. During the capture process,
barcoded library molecules complementary to the biotinylated beads
were retained using streptavidin-coated magnetic beads and PCR-
amplified to generate a final pool of post-capture libraries covering
the targeted chromosomal region on chromosome 16. In total, a pool
of 7 libraries (6 samples and 1 DNA control), covering a 194-kb terri-
tory including the entire PARN gene, was sequenced on an Illumina
HiSeq2500 (paired-end sequencing, 130 × 130 bases, high-throughput
mode, 7 samples on half of a FlowCell lane). After demultiplexing,
sequences were aligned to the reference human genome hg19 using
the Burrows-Wheeler Aligner (Li & Durbin, 2010). The mean depth of
coverage obtained per sample was ≥ 600× to enable more accurate
copy number variation analysis. Downstream processing was carried
out with the Genome Analysis Toolkit (GATK), SAMtools, and Picard,
following documented best practices (http://www.broadinstitute.
org/gatk/guide/topic?name=best-practices). Variant calls were made
with the GATK Unified Genotyper. The annotation process was based
on the latest release of the Ensembl database. Variants were
annotated and analyzed and prioritized using the Polyweb/PolyDiag
software interface designed by the Bioinformatics platform of Univer-
sity Paris Descartes.
Telomere restriction fragment analysis
DNA (800 ng) was digested with HinfI and RsaI enzymes, resolved
by a 0.7% agarose gel, and transferred to a nylon membrane.
Hybridization was performed using EasyHyb solution (Roche) and
c-32P-labeled (TTAGGG)4 probe. After washes, membranes were
exposed over a PhosphorImager (AGFA). PhosphorImager expo-
sures of telomere-probed Southern blots were analyzed with the
ImageJ program. The digitalized signal data were then transferred to
Microsoft Excel and served as the basis for calculating mean TRF
length using the formula L = (ODi)/(ODi/Li), where ODi = inte-
grated signal intensity at position i, and Li = length of DNA frag-
ment in position i.
FISH and Q-FISH
Seeded cells were arrested in metaphase with 60 ng/ml colcemid
(KaryoMAX, Invitrogen) for 30 min, harvested, and resuspended in
75 mM KCl for 15 min at 37°C. Cells were then fixed in 3:1
methanol/acetic acid and dropped onto glass slides. Metaphase
spreads were fixed in 4% formaldehyde in PBS for 2 min and dehy-
drated with sequential immersions into 50, 70, and 100% ethanol
baths for 2 min each and then air-dried. Telomere PNA-FISH was
performed in 70% deionized formamide, 1% blocking reagent
(Roche), and 0.3 lg/ml Cy3-(C3TA2)3 PNA probe (Panagene). DNA
was denatured for 5 min at 80°C, then hybridized for 2 h at room
temperature (RT). Slides were next washed as follows: 2 × 15 min
at RT in 70% formamide, 10 mM Tris pH 7.2 and 3 × 5 min in
50 mM Tris pH 7.5, 150 mM NaCl, and 0.05% Tween-20. Slides
were then dehydrated in ethanol, air-dried, and counterstained with
DAPI mounted in Vectashield (Vector Laboratories) to estimate total
telomere fluorescence intensity in FISH experiments (Q-FISH).
National Institutes of Health software (ImageJ) was used for the
quantitative analysis of images. Telomere intensity in samples was
normalized to fluorescence intensity of telomeric probe labeling
telomeres from Muntjac cells seeded on the same coverslip.
Detection of TIF
For telomere dysfunction-induced foci (TIF) analysis, cells grown on
coverslips were fixed with 2% paraformaldehyde for 10 min,
permeabilized with 0.1% Triton X-100 for 30 min, and incubated
with anti-53BP1 (22760, Santa Cruz; 1:200) for 1h at RT. After
washing and incubation with the secondary antibody, cells were
washed in PBS and dehydrated in sequential ethanol baths, and
FISH was performed as described above.
Senescence-associated b-galactosidase staining
Primary fibroblasts were fixed at room temperature for 10 min in
4% paraformaldehyde in PBS, washed in PBS, and then stained
in b-galactosidase fixative solution (Senescence b-Galactosidase
Staining Kit, # 9860, Cell Signaling) at 37°C for 16 h before cell
imaging.
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Western blotting
Cells were lysed for 20 min on ice in lysis buffer containing 50 mM
Tris (pH 8.0), 2 mM EDTA, 1% Triton X-100, 1% phosphatase inhi-
bitor cocktails (Sigma), and protease inhibitors (Roche). After
centrifugation, the supernatant was harvested and protein concen-
tration was quantified with the Bradford assay. After SDS–PAGE,
proteins were transferred to PVDF Immobilon-P membrane (Milli-
pore). Then, the membrane was incubated for 1h in Odyssey block-
ing buffer (TBS), followed by an incubation with anti-PARN
antibody (Abcam, ab188333, 1:1,000), then washed and incubated
with goat anti-rabbit secondary antibody (Li-Cor IRDye 800CW
Infrared Dye, 1:15,000 dilution). The presence of PARN protein was
detected by infrared fluorescence according to the manufacturer’s
protocol (Odyssey CLx Imaging System). The blot was then incu-
bated with anti-actin or anti-GAPDH (Sigma) as loading control. For
the WB of Fig 4I, 30 lg of protein extracts was processed as
described previously (Arnoult et al, 2012) using the following anti-
bodies: anti-TRF2 (Novus Biologicals, NB110-57130, 1:20,000), anti-
p53 (Santa Cruz, sc-126, 1:10,000), and anti-b-actin (Sigma, A5441,
1:100,000). Secondary antibodies were as follows: anti-rabbit-HRP
(Enzo Life Sciences, ADI-SAB-300-J, 1:10,000) and anti-mouse-HRP
(Abcam, ab205719, 1:2,000). SuperSignal West Pico Chemilumines-
cent Substrate reagent (Thermo Scientific, #34580) was used
for revelation, and signals were quantified on films using ImageJ
software.
hTR FISH
The protocol described in Stern et al (2012) was followed using
12.5 ng of the following FISH probes (Eurofins):
hTR#1: Cy5-GCTGACATTTTTTGTTTGCTCTAGAATGAACGGTGGA
AGGCGGCAGGCCGAGGCTT
hTR#4: Cy5-CTCCGTTCCTCTTCCTGCGGCCTGAAAGGCCTGAACCT
CGCCCTCGCCCCCGAGAG
hTR#5: Cy5-ATGTGTGAGCCGAGTCCTGGGTGCACGTCCCACAGCT
CAGGGAATCGCGCCGCGCGC
siRNA transfection
Transfections with siRNAs were performed as described previously
(Arnoult et al, 2012) using the following siRNAs (Eurogentec):
sip53 (Bergamaschi et al, 2003), 50-CUACUUCCUGAAAACAACG,
and siLuci (Arnoult et al, 2012), 50-CUUACGCUGAGUACUUCGA.
Cells were collected 72 h after transfection.
qRT–PCR
Total RNA was isolated using TriPure reagent (Sigma), and qRT–
PCRs were performed as described previously (Arnoult et al, 2012)
using the primers listed in Appendix Table S2.
Analysis of pre-ribosomal RNA processing
Total RNA isolated from human and mouse cell lines by using TRIzol
was quantified with a NanoDrop spectrophotometer. Samples corre-
sponding to 3 lg total RNAs were separated on a 1.1% agarose gel
containing 1.2% formaldehyde and 1× Tri/Tri buffer (30 mM trietha-
nolamine, 30 mM tricine, pH 7.9), transferred to Hybond N+ nylon
membrane (GE Healthcare), and cross-linked under UV light. After
incubation in hybridization buffer (6× SSC, 5× Denhardt’s solution,
0.5% SDS, 0.9 lg/ml tRNA), the 50-radiolabeled oligonucleotide
probe was added and incubated overnight (45–55°C). The membrane
was washed and exposed to a PhosphorImager screen, which was
revealed using a Typhoon Trio PhosphorImager (GE Healthcare) and
quantified using the MultiGauge software. The human probes used
were as follows:50ETS (50-AGACGAGAACGCCTGACACGCACGGCAC-
30), 50ITS1 (50-CCTCGCCCTCCGGGCTCCGTTAATGATC-30), ITS1-59
(50-GCGGTGGGGGGGTGGGTGTG-30), and a mixture of ITS2-1 (50-CT
GCGAGGGAACCCCCAGCCGCGCA-30) and ITS2-2 (50-GCGCGACGGC
GGACGACACCGCGGCGTC-30). The mouse probes were as follows:
50ITS1 (50-GCTCCTCCACAGTCTCCCGTTAATGATC-30) and ITS2 (50-
ACCCACCGCAGCGGGTGACGCGATTGATCG-30). The same probes
were used to hybridize human and mouse 18S (50-TTTACTTCCTCTA
GATAGTCAAGTTCGACC-30), and 28S rRNAs (50-CCCGTTCCCTTGG
CTGTGGTTTCGCTAGATA-30).
In vitro deadenylation assay
Deadenylation assay was performed as described previously by
Tummala et al (2015). Whole-cell extracts were incubated for 1 h at
30°C in deadenylation buffer (20 mM Tris–HCl pH 7.9, 50 mM
NaCl, 2 mM MgCl2, 10% glycerol, 1 mM b-mercaptoethanol) with
fluorescein-50 labeled 16-mer RNA oligonucleotide (50-CCUUUCC
AAAAAAAA-30). Samples were then heated at 85°C for 3 min in
RNA loading buffer and run in a denaturing PAGE using 20% acry-
lamide:bisacrylamide (19:1) and 50% urea. Results were analyzed
by phosphorimager fluorescent image analyzer FLA-3000 (Fuji-
Film).
Telomerase activity assays
Cells were lysed in 1× CHAPS lysis buffer (TRAPeze S7700, Milli-
pore), and proteins were quantified by Bradford assay (Bio-Rad).
Four dilutions of protein extracts (500, 250, 125, and 62.5 ng) were
assayed for TRAP. TRAP products were separated on TBE/acry-
lamide:bisacrylamide (19:1) gel and visualized by staining with
SYBR Gold Nucleic Acid Gel Stain (Invitrogen).
CRISPR/Cas9 gene inactivation in HT1080 cells
The 50-CCGACTTCTTCGCCATCGAT-30 located in PARN exon 2 was
used as gRNA and cloned into the pX330-U6-Chimeric_BB-
CBhhSpCas9 plasmid (a gift from F. Zhang, the Broad Institute of
Massachusetts Institute of Technology and Harvard University,
Cambridge, MA; plasmid 42230; Addgene; Ran et al, 2013) for
transfection into HT1080 cells. Cells were then cloned and assessed
by Sanger sequencing for the presence of PARN mutations.
Generation of Parn KO mouse model
The generation of Parn KO mice was done in the Mouse Genetics
Engineering Center from Institut Pasteur (Paris, France). All
procedures were reviewed and approved by the Ethics Committee
of Institut Pasteur CETEA (2013-0136). All efforts were made to
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minimize animal suffering and to reduce the number of animals
required for the experiments. A guide RNA sequence was selected
on exon 4 of the murine Parn gene using the CRISPOR Web tool
(http://crispor.tefor.net/crispor.py; Haeussler et al, 2016). Double-
stranded DNA oligonucleotides corresponding to the selected
guide RNA were cloned into the pX330-U6-Chimeric_BB-CBh-
hSpCas9 vector (generous gift from Feng Zhang, Addgene
#42230) according to F. Zhang Lab’s recommendations (Cong
et al, 2013). For mutagenesis scoring and mouse genotyping,
genomic DNA surrounding the guide RNA target sequences was
PCR-amplified (forward: 50-tctggagttgactagtgtcc-30; reverse: 50-
ttcatgctgactgactctgg-30) and the resulting PCR products were
Sanger-sequenced. To generate mutant mouse lines, zygotes were
microinjected with pX330 according to the protocol of Mashiko
et al (2013). F0 mice were obtained, and tail DNA was analyzed
by Sanger sequencing after PCR amplification of the Parn-targeted
locus. F0 mice were crossed onto C57BL6/J to segregate the
CRISPR/Cas9-generated mutant alleles. Two F0-derived F1 mice
(#25 and #29) were selected. CRISPR/Cas9 mutagenesis resulted
in a 2 base-pair deletion in #25 and a 1 base-pair deletion in #29
and subsequent frameshift in both cases (Appendix Fig S6). Each
line was then backcrossed up to 7 times on C57BL6/J (B6) to
segregate away any off-target event outside of chromosome 16.
PCR amplification and direct sequencing of the eleven genomic
loci predicted by the CRISPOR Web tool to be putatively off-
targeted did not reveal any mutation in Parn+/ heterozygous
animals (Appendix Table S1).
Mice
The p53/ mice were described previously (Vera et al, 2013)
and are on a mixed B6/129 background and maintained by
backcrosses onto the C57BL6/J strain. All mice were housed and
handled in TAAM-CNRS-UPR44-Orle´ans animal facility (Agree-
ment number n°D45-234-6, CNRS, France). Mice were kept in a
temperature-controlled environment with a 12-h/12-h light–dark
cycle, with a standard diet and water ad libitum. All animals
were treated in accordance with the Guide for the Care and Use
of Laboratory Animals as adopted by INSERM with full respect
to the EU Directive 2010/63/EU for animal experimentation.
After genotyping, all the mice were euthanized. All the experi-
ments were performed under appropriate license from the local
ethical committee and the French Ministry of Education and
Research (#01501.03).
Statistical analyses
Various Web tools and Microsoft Excel were used for statistical
analyses. When needed, the Shapiro–Wilk test was applied to
check for normal distribution of the data (http://www.sthda.c
om/french/rsthda/shapiro-wilk.php). For the graph of Fig 2D,
normal distribution was not observed (P < 0.05). The Bartlett
test for comparison of variances was applied that similarly led
to exclude the hypothesis of a similarity of variance between the
groups. We thus applied the Kruskal–Wallis non-parametric test
for data of Fig 2D. For Figs 2I and J, and 4A, a chi-square test
was applied that does not require any Shapiro–Wilk test. Similar-
ity of the variance between the compared groups was assessed
by a Bartlett test (https://biostatgv.sentiweb.fr/?module=tests/
anova). When normal distribution was observed, the Student’s
t-test was used to compare the differences between means using
Excel. When P values provided by the Bartlett test were lower
than 0.05, the correction for unequal variance was applied for
Student’s t-tests. In the absence of normal distribution of the
data, the non-parametric Kruskal–Wallis test was used (http://
astatsa.com/KruskalWallisTest/). The chi-square test was also
applied in some cases where the number of observations was
really high (above 1,400) using https://www.socscistatistics.com/
tests/chisquare/default2.aspx and Excel. Most graphs indicate
s.e.m. (standard error of the mean), and the number of repli-
cates is provided in the figure legends.
For the mouse study, by using G*Power tool, we established
that, to demonstrate a lethality with crossing of hetXhet animals,
with a power of 0.8 and a P value < 0.05, 11 animals were required.
We obtained in total 96 animals without homo mice, demonstrating
the lethality. The same holds true with embryos (15 animals
analyzed).
Data availability
Sequence data have been deposited at the European Genome-
phenome Archive (EGA), which is hosted by the EBI and the CRG,
under accession number EGAS00001003623.
Expanded View for this article is available online.
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